Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Danielle S WallaceChris RowlandBrian T HillAndrea M BaranCarla CasuloPatrick M ReaganAllison M WinterReem KarmaliJane N WinterLeo I GordonAndrew BuiPeter SportelliHari P MiskinMichael S WeissJonathan W FriedbergShuo MaPaul M BarrPublished in: Leukemia & lymphoma (2023)